Flputnam Investment Management Co. Buys 826 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Flputnam Investment Management Co. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,070 shares of the biopharmaceutical company’s stock after acquiring an additional 826 shares during the quarter. Flputnam Investment Management Co.’s holdings in Gilead Sciences were worth $492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $210,000. Abundance Wealth Counselors purchased a new position in Gilead Sciences during the third quarter valued at $1,881,000. Toronto Dominion Bank raised its stake in Gilead Sciences by 66.6% during the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock valued at $96,589,000 after buying an additional 515,191 shares during the last quarter. Hussman Strategic Advisors Inc. raised its stake in Gilead Sciences by 11.7% during the third quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 4,400 shares during the last quarter. Finally, Brandywine Global Investment Management LLC raised its stake in Gilead Sciences by 33.9% during the third quarter. Brandywine Global Investment Management LLC now owns 1,535,016 shares of the biopharmaceutical company’s stock valued at $115,034,000 after buying an additional 388,482 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GILD shares. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Finally, Wells Fargo & Company decreased their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and an average target price of $85.36.

Gilead Sciences Stock Performance

Shares of GILD opened at $66.93 on Thursday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences, Inc. has a one year low of $66.89 and a one year high of $87.86. The firm has a market capitalization of $83.33 billion, a P/E ratio of 14.87, a PEG ratio of 0.92 and a beta of 0.19. The business has a fifty day moving average of $72.25 and a 200 day moving average of $76.66.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the firm posted $1.67 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.60%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.